AR037975A1 - El uso de antagonista del receptor h4 de histamina para el tratamiento de respuestas inflamatorias - Google Patents
El uso de antagonista del receptor h4 de histamina para el tratamiento de respuestas inflamatoriasInfo
- Publication number
- AR037975A1 AR037975A1 ARP020105065A ARP020105065A AR037975A1 AR 037975 A1 AR037975 A1 AR 037975A1 AR P020105065 A ARP020105065 A AR P020105065A AR P020105065 A ARP020105065 A AR P020105065A AR 037975 A1 AR037975 A1 AR 037975A1
- Authority
- AR
- Argentina
- Prior art keywords
- histamine
- treatment
- inflammatory responses
- receptor
- inflammation
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001340 histamine Drugs 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 102000004187 Histamine H4 receptors Human genes 0.000 abstract 6
- 108090000796 Histamine H4 receptors Proteins 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000006698 induction Effects 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 230000028709 inflammatory response Effects 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 210000000224 granular leucocyte Anatomy 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000004952 protein activity Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se relaciona con el uso de moduladores del receptor H4 de histamina para la prevención, tratamiento, inducción u otra modulación deseada de las respuestas inflamatorias, inflamación o enfermedades y/o condiciones que son moduladas, afectadas o causadas por inflamación o respuestas inflamatorias. La presente además se relaciona con el uso de moduladores del receptor H4 de histamina para la prevención, tratamiento, inducción u otra modulación deseada de las respuestas de leucocitos polimorfonucleares, tales como migración a un sitio particular, o enfermedades y/o condiciones que son moduladas, afectadas o causadas por leucocitos polimorfonucleares. La presente también se relaciona con el uso de moduladores del receptor H4 de histamina para la prevención, tratamiento, inducción u otra modulación deseada de las respuestas de mastocitos, tales como la degranulación, ó enfermedades y/o condiciones que son moduladas, afectadas o causadas por mastocitos. Reivindicación 1: Un método de identificación de compuestos que modulan la actividad de proteína de receptor H4 de histamina de mamífero, que comprende: a) combinar un compuesto modulador putativo de actividad de proteína de receptor H4 de histamina de mamífero con proteína de receptor H4 de histamina de mamífero y un ligando de receptor de H4 de histamina conocido; y b) medir un efecto del modulador sobre la función de la proteína ó su capacidad para ligar al ligando, en donde dicho efecto es la inhibición, activación, actividad antagonista, agonista o de agonista inverso, en donde dicho compuesto modulador de la inflamación ó de las respuestas inflamatorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/036,648 US20030133931A1 (en) | 2001-12-21 | 2001-12-21 | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037975A1 true AR037975A1 (es) | 2004-12-22 |
Family
ID=21889815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020105065A AR037975A1 (es) | 2001-12-21 | 2002-12-20 | El uso de antagonista del receptor h4 de histamina para el tratamiento de respuestas inflamatorias |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030133931A1 (es) |
| EP (1) | EP1458885A2 (es) |
| JP (1) | JP2005539207A (es) |
| AR (1) | AR037975A1 (es) |
| AU (1) | AU2002348265A1 (es) |
| CA (1) | CA2471214A1 (es) |
| TW (1) | TW200306206A (es) |
| WO (1) | WO2003057919A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
| CA2497788A1 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
| US20080102476A1 (en) * | 2003-09-26 | 2008-05-01 | Lars Karlsson | Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood |
| US9138431B2 (en) | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| US9345697B2 (en) | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2546407B1 (fr) * | 1983-05-24 | 1986-04-18 | Therapeutique Applic Sa | Medicament a activite anti-allergique pour administration locale a base d'acide n-acetyl(a,b)-aspartyl glutamique |
| WO2001085786A2 (en) * | 2000-05-05 | 2001-11-15 | Wyeth | Human histamine h4 receptor |
| GB0101223D0 (en) * | 2001-01-17 | 2001-02-28 | Pfizer Ltd | Histamine receptor antagonists |
-
2001
- 2001-12-21 US US10/036,648 patent/US20030133931A1/en not_active Abandoned
-
2002
- 2002-12-02 WO PCT/US2002/038308 patent/WO2003057919A2/en not_active Ceased
- 2002-12-02 CA CA002471214A patent/CA2471214A1/en not_active Abandoned
- 2002-12-02 JP JP2003558212A patent/JP2005539207A/ja active Pending
- 2002-12-02 AU AU2002348265A patent/AU2002348265A1/en not_active Abandoned
- 2002-12-02 EP EP02782397A patent/EP1458885A2/en not_active Withdrawn
- 2002-12-20 TW TW091136902A patent/TW200306206A/zh unknown
- 2002-12-20 AR ARP020105065A patent/AR037975A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002348265A1 (en) | 2003-07-24 |
| EP1458885A2 (en) | 2004-09-22 |
| US20030133931A1 (en) | 2003-07-17 |
| TW200306206A (en) | 2003-11-16 |
| WO2003057919A3 (en) | 2003-10-30 |
| JP2005539207A (ja) | 2005-12-22 |
| WO2003057919A2 (en) | 2003-07-17 |
| CA2471214A1 (en) | 2003-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414918A (pt) | compostos de benzoimidazola | |
| MX9706069A (es) | Nuevos inhibidores de la trombina. | |
| DE69728893T2 (de) | N-aryl substituierte tetrahydrochinoline ligande für retinoidrezeptoren mit agonist, antagonist oder inverser agonist wirkung | |
| ES2157994T3 (es) | Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa. | |
| ES2059841T3 (es) | Nitro compuestos con actividad insecticida. | |
| IL215027A (en) | Anti-zb7r1 antibody, a formula containing it, and a method of increasing lymphocyte activity with its help | |
| UY28623A1 (es) | Derivados de pirazol y usos de los mismos | |
| BR0211915A (pt) | Execução de aplicação habilitada para teste | |
| NZ602700A (en) | Frizzled-binding agents and uses thereof | |
| ATE247667T1 (de) | Gdnf-rezeptor und dessen verwendung | |
| BR9810456A (pt) | Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico | |
| DK0970095T3 (da) | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase | |
| ECSP045399A (es) | Derivados de quinolina e isoquinolina, un método para su preparación y su uso como inhibidores de la inflamación | |
| EA200000251A1 (ru) | Производные резорцинола | |
| MX9307974A (es) | Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso. | |
| EA200201119A1 (ru) | Лиганды меланокортиновых рецепторов | |
| DK0975359T3 (da) | Anvendelse af forbindelser, der binder en cytoplasmisk dipeptidase til synergistisk virkning af immunreaktionen | |
| BR0210720A (pt) | Composto e uso do mesmo | |
| BR0303482A (pt) | Aparelho para uso no controle e/ou nos testes de um sistema de produção de hidrocarboneto | |
| BR9910908A (pt) | Indenopirrolocarbazóis ligados em ponte | |
| AR037975A1 (es) | El uso de antagonista del receptor h4 de histamina para el tratamiento de respuestas inflamatorias | |
| ATE417285T1 (de) | Ulb-ortungssystem zur rettung von lawinenopfern | |
| BRPI0412471A (pt) | ensaio de alta eficácia à base de células mamìferas para a determinação do perfil e a seleção de moduladores putativos de um canal de sódio epitelial, métodos de monitorar a atividade de um canal de sódio epitelial, e de identificar um composto modulador de sabor salgado, um composto que modula henac, e um modulador de enac humano, e, oócito | |
| ATE296446T1 (de) | Modulatoren von insulinrezeptor-aktivität | |
| BR9406223A (pt) | Método para determinar em uma amostra a atividade funcional de um componente da coagulação sanguinea método para diagnosticar um disturbio da coagulação/anticoagulação sanguinea preparado de anticorpo linhagem celular uso de fator v subunidades ou fragmentos do mesmo tendo atividade anticoagulante na forma de cofator par apc prepraro de plasma embalado plasma deficiente em atividade anticoagulante de fator v como cofator para apc uso do preparado de anticorpo preparado de proteina s preparado de |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |